Business Standard

Sun Pharma gains on acquisition of URL generic biz

Upon completion of the purchase, the non-colcrys generic assets of URL Pharma will be owned and managed by Caraco.

Related News

Sun Pharmaceutical Industries is trading higher by 2% at Rs 732 after the company said it has buys generic business of pharma through its subsidiary for an undisclosed amount.

“Caraco Pharmaceutical Laboratories, wholly-owned subsidiary of the company, has entered into a definitive agreement with Pharmaceuticals U.S.A., Inc, a wholly-owned subsidiary of Takeda Pharmaceutical Company, to buy the URL Pharma, Inc. generic business,” said in a statement.

Upon completion of the purchase, the non-colcrys generic assets of URL Pharma will be owned and managed by Caraco. The deal is subject to satisfaction of customary closing conditions, including applicable regulatory approvals, it added.

The stock opened at Rs 727 and hit a high of Rs 733 on the NSE. A combined 138,547 shares have changed hands on the counter in morning deals.

Read more on:   
|
|

Read More

Two entities fail to make prima facie case to revoke ban: Sebi

The Securities and Exchange Board of India (Sebi) today said the restraining order on two entities, related to plunge in some mid-cap stocks in July, ...

Quick Links

Market News

Markets rise on ECB tide

World markets rallied on Friday after the European Central Bank decided on Thursday to pump a little over about euro 1 trillion to revive the ...

ECB's QE unlikely to result in widespread gains for all asset classes

Cheap money to seek high-yielding assets; prices of others like industrial metals, gold could settle

Sensex records sharpest seven-day rally since 2009

The Sensex surged 273 points on Friday to close at 29,278.84, and has rallied 1,932 points in the past seven trading days since January 15

Gold imports came to halt as discounts widened

High discounts are due to huge carry over stock of gold imported in November

GSK Pharma, select MNC stocks gain as Sebi eases delisting norm

In intra-day trade, GSK Pharma gained as much as 12% and ended 6.4% higher at Rs 3,347.45

 

Back to Top